The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH

被引:5
作者
Chowers, Y. [1 ]
Atarot, T. [1 ]
Pratha, V. S. [2 ]
Fass, R. [3 ,4 ]
机构
[1] Vecta Ltd, Raanana, Israel
[2] Clin Applicat Lab, San Diego, CA USA
[3] So Arizona VA Hlth Care Syst, Tucson, AZ USA
[4] Univ Arizona, Hlth Sci Ctr, Tucson, AZ USA
关键词
gastroesophageal reflux disease; nighttime gastric acid reflux; nighttime heartburn; omeprazole; succinic acid; GASTROESOPHAGEAL-REFLUX DISEASE; GASTRIC-ACIDITY; ESOMEPRAZOLE; LANSOPRAZOLE; SLEEP;
D O I
10.1111/j.1365-2982.2012.01884.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Parietal cell H+/K+ATPase activation is essential for optimal proton pump inhibitor (PPI) activity. Succinic acid (SA) was shown to induce gastric acid secretion. VECAM is a combination of omeprazole (OMP) and SA. To compare the effect of once daily bedtime dosing of VECAM 40 and VECAM 20 without food vs OMP 20 mg administered before breakfast on gastric acidity. Methods Open label, randomized, crossover study enrolling 36 healthy subjects comparing the study treatments at steady state for 24 h intragastric pH monitoring. Key Results The median percent time intragastric pH > 4 demonstrated that VECAM 40 was superior to VECAM 20 (65.7% vs 49.1% P < 0.0001) and OMP 20 mg (65.7% vs 47.6% P = 0.005) during 24 h. VECAM 40 was superior to VECAM 20 (52.8% vs 38.8% P = 0.0079) and OMP 20 mg (52.8% vs 27.2% P < 0.0001), and VECAM 20 was superior to OMP 20 mg (38.8 vs 27.2 P = 0.0069) during the nighttime. VECAM 20 and OMP 20 mg were comparable during 24 h. Conclusions & Inferences VECAM 40 and VECAM 20 were significantly better in maintaining intragastric pH > 4 during the nighttime than OMP 20 mg. Succinic acid eliminates the need for a subsequent meal for intragastric pH control by VECAM.
引用
收藏
页码:426 / +
页数:8
相关论文
共 20 条
  • [1] Chewers Y, 2008, GASTROENTEROLOGY, V134, pA172
  • [2] Chowers Y, 2008, GASTROENTEROLOGY S1, V134
  • [3] Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups
    Dickman, R.
    Parthasarathy, S.
    Malagon, I. B.
    Jones, P.
    Han, B.
    Powers, J.
    Fass, R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (01) : 41 - 48
  • [4] The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life
    Farup, C
    Kleinman, L
    Sloan, S
    Ganoczy, D
    Chee, E
    Lee, C
    Revicki, D
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) : 45 - 52
  • [5] Fass R, 2008, NIGHT TIME GERD APPR, P1
  • [6] Fass R, 2006, MEDSCAPE GASTROENTER, V8, P1
  • [7] Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease
    Gunaratnam, NT
    Jessup, TP
    Inadomi, J
    Lascewski, DP
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (10) : 1473 - 1477
  • [8] Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough
    Hammer, J
    Schmidt, B
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (10) : 1105 - 1110
  • [9] Proton pump inhibitors: better acid suppression when taken before a meal than without a meal
    Hatlebakk, JG
    Katz, PO
    Camacho-Lobato, L
    Castell, DO
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) : 1267 - 1272
  • [10] Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms
    Katz, P. O.
    Koch, F. K.
    Ballard, E. D.
    Bagin, R. G.
    Gautille, T. C.
    Checani, G. C.
    Hogan, D. L.
    Pratha, V. S. V.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (02) : 197 - 205